Menu
Annual · values202520242023
Operating Cash Flow-55.31 M USD-32.84 M USD19.35 M USD
Depreciation & Amortization323000 USD258000 USD195000 USD
Stock-Based Compensation10.04 M USD6.80 M USD2.22 M USD
Capital Expenditures231000 USD514000 USD414000 USD
Cash Flow from Investing-3.71 M USD-69.74 M USD-65.57 M USD
Cash Flow from Financing112.69 M USD109.00 M USD56.18 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow-55.54 M USD-33.36 M USD18.93 M USD

Continua Therapeutics Inc. is a biotechnology company focused on the development and commercialization of innovative therapeutic solutions. Its primary function lies in advancing novel drug candidates aimed at addressing unmet medical needs within the healthcare sector. The company emphasizes research and development, with a focus on diseases that currently lack effective treatment options, potentially impacting various medical fields such as oncology, neurology, and autoimmune disorders. Continua Therapeutics Inc. is significant in the market due to its commitment to pioneering next-generation pharmaceuticals that could redefine standard treatment protocols. Through strategic collaborations and a robust pipeline of research projects, the company plays a critical role in the biotech industry, pushing the boundaries of medical science.